PMN310 demonstrated greater selectivity for target toxic oligomers over monomers compared to other amyloid-beta-directed antibodies. Greater selectivity of PMN310 for toxic oligomers indicates a potentially differentiated profile and supports further development TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 29, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a… Read More..

-Q4 Revenue Exceeds $5 Million for 2nd Time in 2022; Q4 Net Income Increases 12% to $0.25 Million or $0.04 per share- -2022 Revenue Reaches Nearly $20 Million; 2022 Net Income Increases 6-Fold Compared to 2021 to $1.3 Million or $0.21 per share- -Conference Call Friday March 24th at 1:00pm… Read More..

ASHBURN, Va., March 21, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces the dosing of the first patient in its open label clinical trial in Netherton Syndrome patients. The trial is… Read More..